stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) Book value per share
RadNet, Inc.'s book value per share at the end of fiscal 2025 was 18.0×, up 16.2% from 15.5× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 17.9×. Over the past ten years it has ranged from 0.8× (fiscal 2015) to 18.0× (fiscal 2025) — the current reading is the highest in ten years. RadNet, Inc. ranks 15th of 49 Diagnostics & Research companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 18.0× | 16.20% |
| FY2024 | 15.5× | 21.31% |
| FY2023 | 12.8× | 46.53% |
| FY2022 | 8.7× | 32.40% |
| FY2021 | 6.6× | 29.91% |
| FY2020 | 5.1× | 8.14% |
| FY2019 | 4.7× | 12.76% |
| FY2018 | 4.2× | 179.05% |
| FY2017 | 1.5× | 32.51% |
| FY2016 | 1.1× | 35.24% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 17.9× | 2.09% |
| Mar 2026 | 17.6× | (2.65%) |
| Dec 2025 | 18.0× | 4.23% |
| Sep 2025 | 17.3× | 9.08% |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| ICLR ICON PLC compare | 119× |
| GRAL GRAIL, Inc. compare | 52.5× |
| RDNT RadNet, Inc. | 17.9× |
| VCYT Veracyte, Inc. compare | 17.8× |
| QGEN QIAGEN N.V. compare | 16.3× |
| CDNA CareDx, Inc. compare | 9.0× |
| SHC Sotera Health Company compare | 2.6× |
| ADPT Adaptive Biotechnologies Corporation compare | 1.1× |
| BLLN BillionToOne, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement